Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Advanced renal cell carcinoma Age: Adult |
Dose: Oral – 400 mg Frequency: twice daily Note: May continue until patient is no longer responding or unacceptable toxicity occurs. Dose adjustment not necessary for mild to moderate hepatic impairment. Severe hepatic impairment not studied. |
|
Indication: Hepatocellular Carcinoma Age: Adult |
Dose: Oral – 400 mg Frequency: twice daily Note: May continue until patient is no longer responding or unacceptable toxicity occurs. Dose adjustment not necessary for mild to moderate hepatic impairment. Severe hepatic impairment not studied. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild to moderate renal impairment |
Dose: Not specified Note: Dose adjustment not necessary |
|
Condition: Severe renal impairment |
Dose: Not specified Note: Not studied |
Administration
- Take on empty stomach
- Take 1 hour before or 2 hours after meals
Side Effect
- Thrombocytopenia (12-46%)
- Anemia (44%)
- Diarrhea (43%)
- Rash/desquamation (40%)
- Fatigue (37%)
- Abd pain (31%)
- Hand-foot skin reaction (30%)
- Weight loss (30%)
- Anorexia (29%)
- Alopecia (27%)
- Nausea (24%)
- Lymphopenia (23%)
- Neutropenia (18%)
- Hemorrhage (15-18%)
- Hypertension (9-17%)
- Vomiting (16%)
- Constipation (15%)
- Neuropathy (13%)
- Dry skin (11%)
- Headache (10%)
- Joint pain (10%)
- Congestive heart failure
- MI (1.9%)
- QT prolonation (rare)
- Acute renal failure
- Angioedema and arrhythmia may occur
- Bone pain reported
- Stevens-Johnson Syndrome
- Hyperthyroidism
- Interstitial lung disease
- Bleeding fatalities
- Hypertensive crisis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Carbamazepine, Dexamethasone, Phenobarbital, Phenytoin, Rifampicin
|
May decrease sorafenib plasma concentration
|
|
Doxorubicin, Irinotecan
|
May increase plasma concentration of these drugs
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25° C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.